Abiopharma

🔍 Hasan Kazi (Executive)

Company: OPAL Fuels Inc. (OPAL)

Report Date: 2026-03-31

Detailed Transactions and Holdings:

• Acquired 73,415 shares of Class A common stock (Direct)
  Date: 2026-03-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 73,415.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 26,466 shares of Class A common stock at $2.52 per share (Direct)
  Date: 2026-03-31 | Code: F | equity_swap_involved: 0 | shares_owned_after: 46,949.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 146,829 shares of Class A common stock (Direct)
  Date: 2026-03-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 193,778.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 52,931 shares of Class A common stock at $2.52 per share (Direct)
  Date: 2026-03-31 | Code: F | equity_swap_involved: 0 | shares_owned_after: 140,847.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 73,415 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 146,828.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3
• Sold 146,829 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 146,828.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4
• Acquired 182,579 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 182,579.00 | transaction_form_type: 4 | Footnotes: F5, F5, F5
• Acquired 101,988 shares of Stock options (right to buy) at $2.52 per share (Derivative)
  Date: 2026-03-31 | Code: A | Expires: 2036-03-31 | equity_swap_involved: 0 | shares_owned_after: 101,988.00 | transaction_form_type: 4 | Footnotes: F6, F7

Footnotes:

• F1: Each restricted stock unit represents the right to receive, at settlement, one share of Class A common stock. This transaction represents the settlement of restricted stock units in shares of Class A common stock on their scheduled vesting date.
• F2: Represents the shares held by the Company to satisfy tax withholding requirements on vesting of restricted stock units. The total value of securities withheld was based on a price of $2.52 per share, the closing price of Class A common stock on March 31, 2026.
• F3: On March 31, 2025, the Reporting Person was granted 220,243 RSUs pursuant to the Plan. RSUs were scheduled to vest in three (3) equal installments on each of the following dates: (i) March 31, 2026, (ii) March 31, 2027, and (iii) March 31, 2028, provided that the Reporting Person continues to provide services to the Issuer through the applicable vesting date. Each restricted stock unit represents the right to receive, at settlement, one share of Class A common stock.
• F4: On March 31, 2025, the Reporting Person was granted 293,657 RSUs pursuant to the Plan. RSUs were scheduled to vest in two (2) equal installments on each of the following dates: (i) March 31, 2026 and (ii) March 31, 2027, provided that the Reporting Person continues to provide services to the Issuer through the applicable vesting date. Each restricted stock unit represents the right to receive, at settlement, one share of Class A common stock.
• F5: On March 31, 2026, the Reporting Person was granted 182,975 RSUs pursuant to the Plan. RSUs are scheduled to vest in three (3) equal installments on each of the following dates: (i) March 31, 2027, (ii) March 31, 2028, and (iii) March 31, 2029, provided that the Reporting Person continues to provide services to the Issuer through the applicable vesting date. Each restricted stock unit represents the right to receive, at settlement, one share of Class A common stock.
• F6: Granted pursuant to the Issuer's 2022 Omnibus Equity Incentive Plan (the "Plan").
• F7: The Reporting Person was granted an option to purchase shares of the Issuer's Class A common stock (the "Option") at an exercise price of $2.52 per share, which was the volume weighted average price of the Issuer's Class A common stock for the five days immediately preceding March 31, 2026, as quoted on the Nasdaq Stock Market. The Option vests in three (3) equal installments on each of the following dates: (i) March 31, 2027, (ii) March 31, 2028, and (iii) March 31, 2029, provided, that the Reporting Person continues to provide services to the Issuer through the applicable vesting date.
• F8: In the event that the Reporting Person's employment is terminated by reason of the Reporting Person's disability or termination without cause, the Options shall vest with respect to the number of shares of Class A common stock that would have vested upon the next vesting date following such termination, had the Reporting Person remained an employee.
• F9: Notwithstanding the foregoing, upon the occurrence of a termination of employment by reason of the Reporting Person's (i) termination without cause; or (ii) resignation for good reason, in connection with or within the 24 months following the consummation of a Change in Control (as defined in the Plan and the relevant award agreement), any unvested portion of the Option shall accelerate and vest in full.
• F10: Upon the occurrence of a termination by reason of the Reporting Person's death, any unvested portion of the Option shall accelerate and vest in full.